Business
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025
COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual meeting of the American Society for Bone & Mineral Research being held in Seattle from September 5-8, 2025. These include a new analysis of pivotal trial data correlating improvements in leg bowing with improved physical functioning in children with achondroplasia treated with TransCo
About this update from Ascendis Pharma A/s
[{"type":"image","alt":"Ascendis Pharma","displaySize":"","headline":null,"caption":"Ascendis Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1tA.9j4XDPXN.zyLsOvv6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe","width":300,"height":100}},"lazy":false},{"type":"text","content":"COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual meeting of the American Society for Bone & Mineral Research being held in Seattle from September 5-8, 2025. These include a new analysis of pivotal trial data correlating improvements in leg bowing with improved physical functioning in children with achondroplasia treated with TransCon® CNP (navepegritide); the first medical congress presentation of clinical trial data for children with achondroplasia treated with TransCon CNP and TransCon hGH (lonapegsomatropin) combination therapy; and clinical trial data demonstrating the sustained improvements in skeletal dynamics in adults with hypoparathyroidism treated for 4 years with TransCon PTH (palopegteriparatide).","length":888,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:20%;width:20%;min-width:20%;border-bottom:solid black 1pt;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Achondroplasia","length":14,"tagName":"p","attribs":{}}]},{"style":"max-width:80%;width:80%;min-width:80%;border-bottom:solid black 1pt;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"border-bottom:solid black 1pt;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"SaturdaySeptember 612:00 – 12:15 pmGeneral Session Room 6BC","length":63,"tagName":"p","attribs":{}}]},{"style":"border-bottom:solid black 1pt;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Oral PresentationAbstract 1039 (See also poster PM-155.)...